ACP1

Summary

ACP1 (acid phosphatase 1, HGNC:122) is a protein-coding gene on chromosome 2p25.3, encoding Low molecular weight phosphotyrosine protein phosphatase (P24666). Acts on tyrosine phosphorylated proteins, low-MW aryl phosphates and natural and synthetic acyl phosphates with differences in substrate specificity between isoform 1 and isoform 2.

The product of this gene belongs to the phosphotyrosine protein phosphatase family of proteins. It functions as an acid phosphatase and a protein tyrosine phosphatase by hydrolyzing protein tyrosine phosphate to protein tyrosine and orthophosphate. This enzyme also hydrolyzes orthophosphoric monoesters to alcohol and orthophosphate. This gene is genetically polymorphic, and three common alleles segregating at the corresponding locus give rise to six phenotypes. Each allele appears to encode at least two electrophoretically different isozymes, Bf and Bs, which are produced in allele-specific ratios. Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene.

Source: NCBI Gene 52 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 82 total — 25 pathogenic, 2 likely-pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004300

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:122
Approved symbol	ACP1
Name	acid phosphatase 1
Location	2p25.3
Locus type	gene with protein product
Status	Approved
Aliases	HAAP, LMW-PTP, LMWPTP
Ensembl gene	ENSG00000143727
Ensembl biotype	protein_coding
OMIM	171500
Entrez	52

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 12 protein_coding, 4 nonsense_mediated_decay, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000272065, ENST00000272067, ENST00000405233, ENST00000405364, ENST00000407983, ENST00000413140, ENST00000439645, ENST00000442386, ENST00000453390, ENST00000463831, ENST00000480874, ENST00000484125, ENST00000484464, ENST00000896686, ENST00000896687, ENST00000896688, ENST00000896689, ENST00000896690, ENST00000896691, ENST00000972067

RefSeq mRNA: 3 — MANE Select: NM_004300 NM_001040649, NM_004300, NM_007099

CCDS: CCDS1639, CCDS1640, CCDS46217

Canonical transcript exons

ENST00000272065 — 6 exons

Exon	Start	End
ENSE00001380378	277227	278283
ENSE00001907935	264947	265007
ENSE00003574380	271866	271939
ENSE00003591486	275140	275201
ENSE00003624955	276980	277085
ENSE00003641148	272037	272150

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 98.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 86.7782 / max 761.2588, expressed in 1825 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
18536	77.3600	1824
18535	9.4182	1780

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	98.85	gold quality
adrenal tissue	UBERON:0018303	98.79	gold quality
male germ cell	CL:0000015	98.63	gold quality
calcaneal tendon	UBERON:0003701	98.26	gold quality
left adrenal gland	UBERON:0001234	98.23	gold quality
right adrenal gland cortex	UBERON:0035827	98.21	gold quality
right adrenal gland	UBERON:0001233	98.20	gold quality
left adrenal gland cortex	UBERON:0035825	98.20	gold quality
adrenal cortex	UBERON:0001235	97.97	gold quality
adrenal gland	UBERON:0002369	97.95	gold quality
ventricular zone	UBERON:0003053	97.93	gold quality
islet of Langerhans	UBERON:0000006	97.91	gold quality
body of pancreas	UBERON:0001150	97.89	gold quality
embryo	UBERON:0000922	97.87	gold quality
right testis	UBERON:0004534	97.87	gold quality
left testis	UBERON:0004533	97.76	gold quality
ganglionic eminence	UBERON:0004023	97.64	gold quality
pancreas	UBERON:0001264	97.56	gold quality
rectum	UBERON:0001052	97.43	gold quality
palpebral conjunctiva	UBERON:0001812	97.29	gold quality
gall bladder	UBERON:0002110	97.16	gold quality
left ovary	UBERON:0002119	97.15	gold quality
testis	UBERON:0000473	97.08	gold quality
eye	UBERON:0000970	97.06	gold quality
body of stomach	UBERON:0001161	97.05	gold quality
metanephros cortex	UBERON:0010533	96.89	gold quality
adenohypophysis	UBERON:0002196	96.83	gold quality
right ovary	UBERON:0002118	96.81	gold quality
monocyte	CL:0000576	96.74	gold quality
adult organism	UBERON:0007023	96.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

36 targeting ACP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-132-3P	99.73	70.56	1424
HSA-MIR-212-3P	99.73	70.65	1424
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-4672	99.50	71.58	2893
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-16-2-3P	99.29	70.60	1954
HSA-MIR-195-3P	99.29	70.61	1954
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-3675-3P	99.09	67.70	968
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-4724-5P	98.87	67.75	1324
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-8060	98.61	66.93	1187
HSA-MIR-548AO-5P	98.55	69.57	1362
HSA-MIR-548AX	98.55	69.58	1362
HSA-MIR-1248	98.47	67.54	1314
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463

Literature-anchored findings (GeneRIF, showing 40)

• Mycobacteriophage Fruitloop gp52 protein confers heterotypic superinfection exclusion by inactivating Mycobacterium smegmatis protein Wag31. (PMID:29488662)
• ACP1 is associated with allergy (PMID:12100313)
• Association of the ACP1 genotype with metabolic parameters upon initial diagnosis of type 1 diabetes. (PMID:12640337)
• LMW-PTP has a role in immunological synapse establishment and stabilization through the negative control of FAK activity and of cell surface receptor redistribution (PMID:12815062)
• The analysis involved the data on nine polymorphic codominant loci: HP, GC, TF, PI, PGM1, GLO1, C3, ACP1, and ESD. The loci were selected by significance of differences in genotype frequencies between tuberculosis patients and healthy controls (PMID:12942785)
• We show that the association of STAT5 and LMW-PTP does not exclusively involve the phosphatase active site and phosphotyrosine residue of STAT5. (PMID:14637146)
• acid phosphatase 1 contributes to the clinical manifestations of type 2 diabetes and probably also have a marginal influence on susceptibility to the disease (PMID:15281007)
• complex interaction among maternal age, sex of infant and ACP1 concerning age at diagnosis of diabetes (PMID:15586390)
• Finds ACP1*C is a recessively deleterious allele that reduces viability during early life stages and is not maintained by overdominant selection in European populations. (PMID:15974295)
• Significant correlations between LMW-PTP overexpression and the most common clinical-pathological features of cancers exist. In colon cancer and neuroblastoma increased total LMW-PTP mRNA expression correlates with unfavourable outcome. (PMID:16036221)
• Crystal structure of the second human low molecular weight PTPase isoenzyme provides the opportunity to examine the structural basis of different substrate and inhibitor/activator responses. (PMID:16253994)
• mother/newborn pairs: ACP1 (acid phosphatase 1)distribution has fewer pairs with maternal low ACP1 S isoform and infant high S isoform concentration;Recurrent spontaneous abortion couples show wife low S isoform and husband high S isoform concentration (PMID:16762482)
• GRX plays an important role in PDGF-BB-dependent cell proliferation by regulating the redox state of LMW-PTP (PMID:16893901)
• Among newborns carrying the ACP1C allele there is an increase of Sex Ratio among the offspring of smoking mothers relative to non-smoking mothers. (PMID:16973312)
• Human recombinant LMWPTP-A displayed an RN5Pase activity that was higher than its tyrosine phosphatase activity, indicating that this phosphatase may participate in protein deglycation, a new form of protein repair. (PMID:17472574)
• results suggest a cooperative effect of ADA and ACP1 genetic polymorphism on the susceptibility to repeated spontaneous abortion and to some of its clinical characteristics (PMID:17565542)
• Women homozygous for haptoglobin with low ACP1 activity are more likely to conceive in the first part of the year. Women heterozygous for haptoglobin with medium-high ACP1 activity are more likely to conceive in the last part of the year. (PMID:17678914)
• There is a significant negative correlation between the intensity of skin test reaction and the ACP1 *B/*C genotype in allergic individuals. (PMID:17703100)
• The increase of fast isozyme concentration increased the invasive capacity of cancer cells, whereas a decrease of slow isozyme concentration in cancer did not cause growth inhibition and so resulted in cancer cell proliferation. (PMID:18262048)
• These findings suggest that carriers of high activity ACP1 genotypes are more susceptible to endometriosis but less susceptible to allergic manifestations than carriers of other ACP1 genotypes. (PMID:18490013)
• Highly significant differences in birth weight-placental weight correlations were observed among acid phosphatase locus 1 phenotypes. (PMID:18768081)
• There is an increase of the *B/*B genotype (high F isoform) & a much more marked decrease of genotypes with the high S isoform in colon cancer, compared with controls. (PMID:18786445)
• High concontration of the ACP1 F isoform may negatively regulate cell proliferation and growth of leiomyomas through dephosphorylation of the PDGF receptor. (PMID:18992867)
• Present in adipocytes, this protein may have a specific role in the regulation of quantity of adipose tissue. (PMID:19217450)
• ACP1 may be involved in susceptibility to coronary artery disease (PMID:19246900)
• The present data suggest an epistatic action of ACP1 concerning the effect of Hp on the susceptibility to convulsive disorders. (PMID:19569002)
• A possible protective effect of ACP1 genotype against cardiovascular risk factors was observed in this study (PMID:19570551)
• Variation in ACP1 is associated with fasting insulin and insulin sensitivity in a sex-specific manner. There is a sex-specific effect of variation in ACP1 to alter insulin signaling. (PMID:19622628)
• A significant interaction between ACP1 and ADA1 concerning susceptibility to type 1 diabetes, was revealed. (PMID:19789510)
• In overweight women (BMI > 25), the proportion of low activity ACP1 phenotypes is much lower in type 1 diabetes than in gestational diabetes and in healthy females. (PMID:19855922)
• the correlation between blood glucose and glycated Hb in relation to AK1 and ACP1 polymorphism was studied. (PMID:20152999)
• association with coronary artery disease evident only in diabetic subjects and dependent on female gender (PMID:20581655)
• Type 1 diabetes subjects show a highly significant increase of ACP1*A/ADA1*2 gametic type compared with healthy subjects from the same population (P = 0.003). (PMID:20805743)
• the ACP1 protein is a tyrosine phosphatase that influences Wnt signaling, a pathway regulated by lithium, making ACP1 a functional candidate for involvement in the phenotype. (PMID:21423239)
• Although both variants dephosphorylate the EPHA2 receptor, the rate and specificity of dephosphorylation for specific tyrosines are different for ACP1 and human cytoplasmic protein tyrosine phosphatase-B. (PMID:21538645)
• investigated hypothesis that favism is caused by toxic Vicia faba substances, which in some ACP1 phenotypes cause increased phosphorylation and thus increased glycolysis, with strong reduction in reduced glutathione production, resulting in hemolysis (PMID:21644204)
• the ACP1*C allele influences the risk of cardiovascular disease events in patients with rheumatoid arthritis. (PMID:21767392)
• Gain of the telomeric region 2p25.3 harboring the ACP1 gene is common in CLL (25%, 44 of 178 cases). (PMID:22035742)
• Data indicate that ACP1 rs11553742*T with increased susceptibility in systemic lupus erythematosus (SLE) patients. (PMID:22064183)
• lack of association with inflammatory bowel disease in Spanish patients (PMID:22428720)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Acp1	ENSMUSG00000044573
rattus_norvegicus	Acp1	ENSRNOG00000005260
drosophila_melanogaster	CG14297	FBGN0038655
drosophila_melanogaster	Argp	FBGN0051469

Paralogs (1): PTRHD1 (ENSG00000184924)

Protein

Protein identifiers

Low molecular weight phosphotyrosine protein phosphatase — P24666 (reviewed: P24666)

Alternative names: Adipocyte acid phosphatase, Low molecular weight cytosolic acid phosphatase, Red cell acid phosphatase 1

All UniProt accessions (6): P24666, A0A140VK37, D3YTI2, F2Z2Q9, F2Z2R9, G5E9R5

UniProt curated annotations — full annotation on UniProt →

Function. Acts on tyrosine phosphorylated proteins, low-MW aryl phosphates and natural and synthetic acyl phosphates with differences in substrate specificity between isoform 1 and isoform 2. Does not possess phosphatase activity.

Subunit / interactions. Interacts with EPHA2; dephosphorylates EPHA2. Interacts with EPHB1. Interacts with the SH3 domain of SPTAN1. There is no interaction observed for isoforms 2 or 3.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in T-lymphocytes.

Post-translational modifications. Phosphorylated by LCK. Phosphorylation at Tyr-132 increases its phosphatase activity. Not phosphorylated.

Activity regulation. Inhibited by sulfhydryl reagents.

Polymorphism. ACP1 is genetically polymorphic. Three common alleles are known in Caucasians: ACP1A, ACP1B and ACP1C. They give rise to six different phenotypes. Each allele appears to encode two electrophoretically different isozymes, F and S, which are produced in allele-specific ratios. The sequence shown is that of allele ACP1B and allele ACP1*C.

Similarity. Belongs to the low molecular weight phosphotyrosine protein phosphatase family.

Isoforms (4)

UniProt ID	Names	Canonical?
P24666-1	1, F, A, Alpha, LMPTP-A, HCPTP-A	yes
P24666-2	2, S, B, Beta, LMPTP-B, HCPTP-B
P24666-3	3, C, LMPTP-C
P24666-4	4

RefSeq proteins (3): NP_001035739, NP_004291, NP_009030 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002115	Tyr_Pase_low_mol_wt_mml	Family
IPR017867	Tyr_phospatase_low_mol_wt	Family
IPR023485	Ptyr_pPase	Domain
IPR036196	Ptyr_pPase_sf	Homologous_superfamily
IPR050438	LMW_PTPase	Family

Pfam: PF01451

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 2 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)
• a phosphate monoester + H2O = an alcohol + phosphate (RHEA:15017)

UniProt features (34 total): helix 7, splice variant 4, sequence conflict 4, strand 4, sequence variant 3, mutagenesis site 3, active site 3, modified residue 3, initiator methionine 1, chain 1, turn 1

Structure

Experimental structures (PDB)

17 structures.

PDB	Method	Resolution (Å)
7KH8	X-RAY DIFFRACTION	1.3
5JNT	X-RAY DIFFRACTION	1.45
5KQL	X-RAY DIFFRACTION	1.45
3N8I	X-RAY DIFFRACTION	1.5
5KQG	X-RAY DIFFRACTION	1.5
7UW6	X-RAY DIFFRACTION	1.5
1XWW	X-RAY DIFFRACTION	1.63
6Y2W	X-RAY DIFFRACTION	1.77
5JNS	X-RAY DIFFRACTION	1.8
5KQM	X-RAY DIFFRACTION	1.91
5JNR	X-RAY DIFFRACTION	2
6Y2V	X-RAY DIFFRACTION	2
5KQP	X-RAY DIFFRACTION	2.05
4Z9A	X-RAY DIFFRACTION	2.1
5PNT	X-RAY DIFFRACTION	2.2
4Z99	X-RAY DIFFRACTION	2.3
4Z9B	X-RAY DIFFRACTION	2.41

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P24666-F1	96.16	0.96

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 13 (nucleophile); 19; 130 (proton donor)

Post-translational modifications (3): 2, 132, 133

Mutagenesis-validated functional residues (3):

Position	Phenotype
13	inactive.
132	reduced phosphorylation and activity.
133	reduced phosphorylation. no effect on activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 164 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, AAGCAAT_MIR137, chr2p25, TGCGCANK_UNKNOWN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, KAAB_FAILED_HEART_ATRIUM_DN, MORF_SNRP70, MORF_UBE2I, MORF_HDAC1, MORF_UBE2N, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GOBP_CELL_CELL_SIGNALING, OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP

GO Biological Process (2): chemical synaptic transmission (GO:0007268), protein dephosphorylation (GO:0006470)

GO Molecular Function (8): acid phosphatase activity (GO:0003993), protein tyrosine phosphatase activity (GO:0004725), non-membrane spanning protein tyrosine phosphatase activity (GO:0004726), SH3 domain binding (GO:0017124), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787), phosphatase activity (GO:0016791)

GO Cellular Component (7): cytoplasm (GO:0005737), cytosol (GO:0005829), cytoplasmic side of plasma membrane (GO:0009898), sarcolemma (GO:0042383), synapse (GO:0045202), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
phosphatase activity	2
plasma membrane	2
anterograde trans-synaptic signaling	1
dephosphorylation	1
protein modification process	1
phosphoprotein phosphatase activity	1
protein tyrosine phosphatase activity	1
protein domain specific binding	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
phosphoric ester hydrolase activity	1
intracellular anatomical structure	1
cytoplasm	1
cytoplasmic side of membrane	1
cell junction	1
extracellular vesicle	1

Protein interactions and networks

STRING

2558 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ACP1	G6PD	P11413	772
ACP1	PTS	Q03393	764
ACP1	A0A096LPE2	A0A096LPE2	717
ACP1	SAA4	P35542	711
ACP1	H6PD	O95479	708
ACP1	EPHA2	P29317	672
ACP1	LDHC	P07864	668
ACP1	PTPN1	P18031	650
ACP1	TCN2	P20062	647
ACP1	GSR	P00390	635
ACP1	CTNNB1	P35222	609
ACP1	ARHGAP35	Q9NRY4	597
ACP1	LDHA	P00338	588
ACP1	ESD	P10768	583
ACP1	KCNC1	P48547	582

IntAct

53 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
ACP1	ACTB	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
M	ACP1	psi-mi:“MI:0915”(physical association)	0.400
ERBB2	ACP1	psi-mi:“MI:0915”(physical association)	0.370
ACP1	SFMBT1	psi-mi:“MI:0915”(physical association)	0.370
KSR1	FBLL1	psi-mi:“MI:0914”(association)	0.350
DLD	NFKBIE	psi-mi:“MI:0914”(association)	0.350
COPS5	FBLL1	psi-mi:“MI:0914”(association)	0.350
PRDM11	ERCC3	psi-mi:“MI:0914”(association)	0.350
TEX101	PSMD12	psi-mi:“MI:0914”(association)	0.350
TNK1	ACP1	psi-mi:“MI:0914”(association)	0.350
TESK1	ACACB	psi-mi:“MI:0914”(association)	0.350
RIOK1	SUPT5H	psi-mi:“MI:0914”(association)	0.350
RHOA	TAX1BP3	psi-mi:“MI:0914”(association)	0.350
	AGPS	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
PIP4K2A	SAP18	psi-mi:“MI:0914”(association)	0.350
US3	ACOT8	psi-mi:“MI:0914”(association)	0.350

BioGRID (141): SFMBT1 (Two-hybrid), ABRACL (Co-fractionation), ACP1 (Co-fractionation), ACP1 (Co-fractionation), ACP1 (Co-fractionation), ACP1 (Co-fractionation), PCBP1 (Co-fractionation), PITPNA (Co-fractionation), PPIL3 (Co-fractionation), TALDO1 (Co-fractionation), ACP1 (Affinity Capture-MS), ZBTB43 (Affinity Capture-MS), ACP1 (Affinity Capture-MS), DNAJC13 (Affinity Capture-MS), GADD45GIP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0U1WZ18, A0A1S4A695, A2VE01, A3QK15, O15305, O35621, O46560, P06766, P11064, P24666, P41498, P78330, P81693, P82197, Q0II59, Q148G4, Q1W374, Q1W375, Q1W376, Q1W377, Q259G4, Q2KHU0, Q3SZJ9, Q3T186, Q4R7R3, Q5E982, Q5I0K3, Q5PQL4, Q5RB83, Q5REM7, Q5VST6, Q5ZIV1, Q5ZJ01, Q5ZJL4, Q5ZKG5, Q60HD6, Q6DCC5, Q6DEY3, Q6P1N9, Q6P8M1

Diamond homologs: A0A0H3K9F2, B7INE4, O35016, O52787, P0C5D2, P11064, P24666, P39155, P40347, P41498, P41893, P53433, P58596, P65717, P81693, P82890, P82891, P9WIA0, P9WIA1, Q02191, Q2FFL4, Q2FX12, Q2YU46, Q45408, Q49YS6, Q49Z62, Q4L7J1, Q55535, Q55GW2, Q5HEP3, Q5HN53, Q5REM7, Q5ZKG5, Q6G853, Q6GFH6, Q7A0I2, Q7A4S1, Q8CNQ1, Q99T00, Q9D358

SIGNOR signaling

17 interactions.

A	Effect	B	Mechanism
ACP1	“down-regulates activity”	PDGFRB	dephosphorylation
ACP1	“down-regulates activity”	PTK2	dephosphorylation
ACP1	“up-regulates activity”	PKM	dephosphorylation
ACP1	“up-regulates activity”	SRC	dephosphorylation
ACP1	“down-regulates activity”	AKT1	dephosphorylation
ACP1	“down-regulates activity”	AKT2	dephosphorylation
ACP1	“down-regulates activity”	AKT3	dephosphorylation
ACP1	“down-regulates activity”	AKT	dephosphorylation
ACP1	“down-regulates activity”	EPHA2	dephosphorylation
FYN	“up-regulates activity”	ACP1	phosphorylation
LCK	“up-regulates activity”	ACP1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	25
Likely pathogenic	2
Uncertain significance	25
Likely benign	4
Benign	6

Top pathogenic / likely-pathogenic (27)

Variant ID	HGVS	Classification
1330210	GRCh37/hg19 2p25.3(chr2:10501-2386917)x1	Pathogenic
146223	GRCh38/hg38 2p25.3(chr2:30341-3449132)x1	Pathogenic
146260	GRCh38/hg38 2p25.3(chr2:30341-1969402)x1	Pathogenic
147583	GRCh38/hg38 2p25.3(chr2:39193-1542734)x1	Pathogenic
148175	GRCh38/hg38 2p25.3(chr2:30341-2656139)x1	Pathogenic
148269	GRCh38/hg38 2p25.3-23.3(chr2:17019-26318846)x3	Pathogenic
150293	GRCh38/hg38 2p25.3(chr2:24400-817581)x3	Pathogenic
152888	GRCh38/hg38 2p25.3(chr2:17019-2305267)x1	Pathogenic
153475	GRCh38/hg38 2p25.3(chr2:12770-2748672)x1	Pathogenic
154817	GRCh38/hg38 2p25.3(chr2:131730-2713517)x1	Pathogenic
160975	GRCh38/hg38 2p25.3(chr2:30341-507042)x3	Pathogenic
1808728	GRCh37/hg19 2p25.3(chr2:12771-1947832)x1	Pathogenic
2671972	GRCh37/hg19 2p25.3(chr2:12770-2832894)x1	Pathogenic
3242306	GRCh37/hg19 2p25.3(chr2:11314-3033976)x1	Pathogenic
442997	GRCh37/hg19 2p25.3-q37.3(chr2:12771-242783384)x3	Pathogenic
443675	GRCh37/hg19 2p25.3-24.1(chr2:12770-20081474)x3	Pathogenic
4526718	NC_000002.12:g.100000_1793802del	Pathogenic
562667	GRCh37/hg19 2p25.3-25.2(chr2:12770-4823625)x3	Pathogenic
59131	GRCh38/hg38 2p25.3-24.3(chr2:30342-14866951)x3	Pathogenic
59132	GRCh38/hg38 2p25.3-25.1(chr2:50661-9652907)x3	Pathogenic
686001	GRCh37/hg19 2p25.3(chr2:12770-2832894)x1	Pathogenic
686548	GRCh37/hg19 2p25.3-25.1(chr2:12770-7502796)x3	Pathogenic
686549	GRCh37/hg19 2p25.3-25.1(chr2:12770-7502796)x3	Pathogenic
688279	GRCh37/hg19 2p25.3(chr2:12770-2348876)x1	Pathogenic
814206	GRCh37/hg19 2p25.3(chr2:12770-3000954)x1	Pathogenic
148892	GRCh38/hg38 2p25.3(chr2:17019-1645317)x1	Likely pathogenic
152440	GRCh38/hg38 2p25.3-25.2(chr2:17019-4957745)x3	Likely pathogenic

SpliceAI

1295 predictions. Top by Δscore:

Variant	Effect	Δscore
2:265006:GG:G	donor_gain	1.0000
2:265007:GG:G	donor_gain	1.0000
2:265007:GGTA:G	donor_loss	1.0000
2:265008:GT:G	donor_loss	1.0000
2:265009:T:G	donor_loss	1.0000
2:266309:T:TA	donor_gain	1.0000
2:266310:A:AA	donor_gain	1.0000
2:271861:TAAAG:T	acceptor_loss	1.0000
2:271864:A:AC	acceptor_loss	1.0000
2:271865:G:GA	acceptor_loss	1.0000
2:271936:GAAT:G	donor_gain	1.0000
2:271937:AATG:A	donor_loss	1.0000
2:271938:AT:A	donor_gain	1.0000
2:271938:ATGTA:A	donor_loss	1.0000
2:271939:TGTAA:T	donor_loss	1.0000
2:271940:G:GG	donor_gain	1.0000
2:271941:T:A	donor_loss	1.0000
2:271942:AAG:A	donor_loss	1.0000
2:264977:GC:G	donor_gain	0.9900
2:264985:G:GG	donor_gain	0.9900
2:265008:G:GG	donor_gain	0.9900
2:271935:AGAAT:A	donor_gain	0.9900
2:271936:GAATG:G	donor_gain	0.9900
2:271937:AAT:A	donor_gain	0.9900
2:271943:AGT:A	donor_loss	0.9900
2:272035:A:AG	acceptor_gain	0.9900
2:272036:G:GG	acceptor_gain	0.9900
2:275261:ATTT:A	donor_gain	0.9900
2:276978:A:AG	acceptor_gain	0.9900
2:276979:G:GG	acceptor_gain	0.9900

AlphaMissense

1057 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:271870:C:A	N16K	0.999
2:271870:C:G	N16K	0.999
2:277074:G:C	D130H	0.999
2:277242:T:C	F139L	0.999
2:277244:T:A	F139L	0.999
2:277244:T:G	F139L	0.999
2:265007:G:C	G15R	0.998
2:272049:A:C	S44R	0.998
2:272051:C:A	S44R	0.998
2:272051:C:G	S44R	0.998
2:275181:T:G	C91W	0.998
2:275185:G:C	D93H	0.998
2:277075:A:C	D130A	0.998
2:277075:A:G	D130G	0.998
2:277075:A:T	D130V	0.998
2:277076:T:A	D130E	0.998
2:277076:T:G	D130E	0.998
2:277265:T:G	C146W	0.998
2:265001:T:C	C13R	0.997
2:271866:G:T	G15V	0.997
2:271869:A:T	N16I	0.997
2:271874:T:C	C18R	0.997
2:272097:G:T	G60W	0.997
2:272143:C:A	A75D	0.997
2:275164:T:C	F86L	0.997
2:275166:T:A	F86L	0.997
2:275166:T:G	F86L	0.997
2:275186:A:T	D93V	0.997
2:277038:G:T	G118W	0.997
2:277277:C:G	C150W	0.997

dbSNP variants (sampled 300 via entrez): RS1000129166 (2:266901 T>A,C), RS1000313362 (2:272555 G>A), RS1000332887 (2:278735 G>A,C), RS1000464476 (2:270596 T>G), RS1000602361 (2:273794 T>C), RS1000620127 (2:277372 G>A), RS1000912933 (2:274270 C>T), RS1000997769 (2:263425 G>C), RS1001110613 (2:267309 C>G,T), RS1001288348 (2:270614 A>G), RS1001346205 (2:271535 C>T), RS1001400000 (2:271359 C>T), RS1001509690 (2:278205 T>G), RS1001588921 (2:265495 A>G), RS1001719873 (2:271037 T>A)

Disease associations

OMIM: gene MIM:171500 | disease phenotypes: MIM:616521

GenCC curated gene-disease

Mondo (1): intellectual disability, autosomal dominant 39 (MONDO:0014678)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4903 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 47,045 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL82202	PYRIDOXAL PHOSPHATE ANHYDROUS	3	26,220
CHEMBL169	URSOLIC ACID	2	20,825

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

258 measured of 319 human assays (344 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
cid_694792	KI	60 nM
6-bromo-N-piperonyl-pyrazolo[1,5-a]pyrimidine-2-carboxamide	IC50	363 nM
(E)-3-(3,4-dimethoxyphenyl)-N-[(2-hydroxy-5-nitro-phenyl)thiocarbamoyl]acrylamide	IC50	1090 nM
cid_4640068	IC50	1470 nM
(5Z)-2-azanylidene-3-(4-fluorophenyl)-5-[(4-hydroxyphenyl)methylidene]-1,3-thiazolidin-4-one	IC50	1550 nM
MLS000673878	IC50	1570 nM
4-keto-5-methyl-2-[(E)-2-(4-methyl-3-nitro-phenyl)vinyl]-3H-thieno[2,3-d]pyrimidine-6-carboxylic acid	IC50	1620 nM
N-(3-methylphenyl)-2-[4-[(Z)-2-[5-nitro-2,4-bis(oxidanylidene)-1H-pyrimidin-6-yl]ethenyl]phenoxy]ethanamide	IC50	1780 nM
4-{2-[(5-bromo-3-pyridinyl)carbonyl]carbonohydrazonoyl}phenyl 1,3-benzodioxole-5-carboxylate	IC50	1820 nM
3-[ethyl(phenyl)sulfamoyl]-4-methyl-benzoic acid	IC50	1830 nM
N’-(3-chlorobenzoyl)thieno[2,3-b]quinoline-2-carbohydrazide	IC50	1900 nM
(2Z)-2-[[(2-hydroxyphenyl)-oxomethyl]hydrazinylidene]-1-benzopyran-3-carboxamide	IC50	1930 nM
4-chloranyl-5-[2-[(4-chlorophenyl)methylidene]hydrazinyl]-2-phenyl-pyridazin-3-one	IC50	1930 nM
3-[7-[(2-chlorophenyl)methoxy]-4,8-dimethyl-2-oxochromen-3-yl]propanoic acid	IC50	1990 nM
cid_277512	IC50	1990 nM
MLS001197785	IC50	2090 nM
MLS001213411	IC50	2170 nM
4-[[3-[(5Z)-5-(1,3-benzodioxol-5-ylmethylidene)-4-oxo-2-sulfanylidene-3-thiazolidinyl]-1-oxopropyl]amino]benzoic acid	IC50	2300 nM
MLS001224813	IC50	2380 nM
MLS000576933	IC50	2450 nM
SMR001798128	IC50	2590 nM
cid_1344193	IC50	2640 nM
2-[(6,7-dihydroxy-2-keto-chromen-4-yl)methylthio]-3-(3-methoxyphenyl)quinazolin-4-one	IC50	2720 nM
1-ethyl-6-fluoro-7-[4-[(3-methylbenzoyl)carbamothioyl]piperazin-1-yl]-4-oxoquinoline-3-carboxylic acid	IC50	2740 nM
MLS000776640	IC50	2890 nM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	IC50	2900 nM	US-9522881: Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
2-(1H-indol-5-yl)-N-(3-piperidin-3-ylpropyl)quinolin-4-amine	IC50	2900 nM	US-11220486: Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
2-(3H-benzimidazol-5-yl)-N-(3-piperidin-3-ylpropyl)quinolin-4-amine	IC50	2900 nM	US-11220486: Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
N-(3-piperidin-3-ylpropyl)-2-(1H-pyrrol-2-yl)quinolin-4-amine	IC50	2900 nM	US-11220486: Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
N-(3-piperidin-3-ylpropyl)-2-[4-(tetrazolidin-5-yl)phenyl]quinolin-4-amine	IC50	2900 nM	US-11220486: Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
cid_17252838	IC50	2910 nM
4-({4-[5-(2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]butanoyl}amino)benzoic acid	EC50	2980 nM
3-[7-[(6-chloranyl-1,3-benzodioxol-5-yl)methoxy]-4,8-dimethyl-2-oxidanylidene-chromen-3-yl]propanoic acid	IC50	2990 nM
cid_9652363	IC50	3040 nM
MLS000714465	IC50	3060 nM
cid_4826777	IC50	3080 nM
2-[4-[[6-carbethoxy-3-keto-7-methyl-5-[4-(methylthio)phenyl]-5H-thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]acetic acid	IC50	3140 nM
2-[4-[[5-(4-chlorophenyl)-6-ethoxycarbonyl-7-methyl-3-oxidanylidene-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]ethanoic acid	IC50	3200 nM
MLS000557507	IC50	3200 nM
SMR000606819	IC50	3210 nM
MLS000571311	IC50	3250 nM
N-[(E)-(5-bromanylthiophen-2-yl)methylideneamino]-3-nitro-benzamide	IC50	3400 nM
MLS000558757	IC50	3420 nM
SMR000567889	IC50	3490 nM
MLS001167540	IC50	3800 nM
2-amino-3-(1,3-benzoxazol-2-yl)-1-butyl-6-methyl-4-nitro-7-pyrrolo[2,3-d]pyridazinone	IC50	3870 nM
N-[(E)-[4-(2-anilino-2-oxoethoxy)phenyl]methylideneamino]-2-hydroxybenzamide	IC50	3880 nM
N-[(E)-(3-nitrobenzylidene)amino]benzo[e]benzofuran-2-carboxamide	IC50	3910 nM
SMR000036870	IC50	4060 nM
N-(4-{[3-(3-nitrophenyl)acryloyl]amino}phenyl)-2-thiophenecarboxamide	IC50	4110 nM

ChEMBL bioactivities

455 potent at pChembl≥5 of 578 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.92	Ki	1.2	nM	CHEMBL5218807
8.40	IC50	4	nM	CHEMBL5218807
8.22	IC50	6	nM	CHEMBL4875137
8.10	IC50	8	nM	CHEMBL5219822
7.70	IC50	20	nM	CHEMBL4856707
7.40	Kd	39.49	nM	CHEMBL5653589
7.40	ED50	39.49	nM	CHEMBL5653589
7.31	IC50	49	nM	CHEMBL5218783
7.25	IC50	56	nM	CHEMBL5220687
7.08	IC50	83	nM	CHEMBL4857535
7.06	IC50	87	nM	CHEMBL4855952
6.98	IC50	104	nM	CHEMBL4874911
6.97	IC50	106	nM	CHEMBL4848127
6.93	IC50	117	nM	CHEMBL4873827
6.92	IC50	119	nM	CHEMBL4859307
6.92	IC50	121	nM	CHEMBL5220615
6.83	IC50	147	nM	CHEMBL4858034
6.77	IC50	171	nM	CHEMBL4861843
6.70	IC50	200	nM	CHEMBL5220051
6.66	IC50	220	nM	CHEMBL1765349
6.62	IC50	239	nM	CHEMBL4847980
6.62	IC50	239	nM	CHEMBL4870698
6.61	IC50	245	nM	CHEMBL4868378
6.57	Ki	270	nM	CHEMBL515146
6.54	IC50	288	nM	CHEMBL4857590
6.52	IC50	300	nM	CHEMBL5218478
6.52	IC50	300	nM	CHEMBL5219403
6.51	IC50	306	nM	CHEMBL4852414
6.47	IC50	340	nM	CHEMBL2396718
6.47	Ki	340	nM	CHEMBL515146
6.42	IC50	380	nM	CHEMBL4846731
6.40	IC50	400	nM	CHEMBL5218609
6.40	IC50	400	nM	CHEMBL5219065
6.30	IC50	500	nM	CHEMBL1765349
6.30	IC50	500	nM	CHEMBL5865295
6.30	IC50	500	nM	CHEMBL6023401
6.30	IC50	500	nM	CHEMBL6010131
6.30	IC50	500	nM	CHEMBL5812199
6.30	IC50	500	nM	CHEMBL5954976
6.30	IC50	500	nM	CHEMBL5811959
6.30	IC50	500	nM	CHEMBL5821488
6.30	IC50	500	nM	CHEMBL5902805
6.30	IC50	500	nM	CHEMBL5964614
6.30	IC50	500	nM	CHEMBL5925675
6.30	IC50	500	nM	CHEMBL5783597
6.30	IC50	500	nM	CHEMBL5993213
6.30	IC50	500	nM	CHEMBL5772777
6.30	IC50	500	nM	CHEMBL5900713
6.30	IC50	500	nM	CHEMBL5946013
6.30	IC50	500	nM	CHEMBL5863654

PubChem BioAssay actives

135 with measured affinity, of 413 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(3,5-dibromo-4-methylphenyl)carbamoylsulfamic acid	1917679: Competitive inhibition of LMW-PTP (unknown origin) assessed as inhibition constant by Lineweaver-Burk plot analysis	ki	0.0012	uM
3-[(3,5-dichloro-4-pyridinyl)methyl]-8-(2-methylphenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.0060	uM
azane;(3-bromo-4-morpholin-4-ylphenyl)carbamoylsulfamic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.0080	uM
3-[(2,6-dichlorophenyl)methyl]-8-(2-methylphenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.0200	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147788: Binding affinity to human ACP1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0395	uM
azane;1,3-thiazol-2-ylcarbamoylsulfamic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.0490	uM
azane;1,3-benzothiazol-2-ylcarbamoylsulfamic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.0560	uM
3-[(3,5-dichloro-4-pyridinyl)methyl]-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.0830	uM
3-[(2,6-dichlorophenyl)methyl]-8-(3-methylphenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.0870	uM
3-[(2,6-dichlorophenyl)methyl]-8-phenyl-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.1040	uM
3-[(2,6-dichlorophenyl)methyl]-8-(2-methoxyphenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.1060	uM
3-[(2,6-dichlorophenyl)methyl]-8-(4-fluorophenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.1170	uM
3-[(2,6-dichlorophenyl)methyl]-8-(4-methylphenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.1190	uM
azane;phenylcarbamoylsulfamic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.1210	uM
3-[(2,6-dichlorophenyl)methyl]-8-(2-fluorophenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.1470	uM
8-(2-chlorophenyl)-3-[(2,6-dichlorophenyl)methyl]-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.1710	uM
2-[(6-nitro-1,3-benzothiazol-2-yl)amino]-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.2000	uM
4-[[(5Z)-5-[[3-[(4-carboxyphenyl)methoxy]phenyl]methylidene]-4-oxo-2-phenylimino-1,3-thiazolidin-3-yl]methyl]benzoic acid	696430: Inhibition of human LMW-PTPase isoform 2	ic50	0.2200	uM
3-[(2,6-dichlorophenyl)methyl]-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.2390	uM
3-[(2,6-dichlorophenyl)methyl]-8-(3-fluorophenyl)-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.2390	uM
2-[3-[(2,6-dichlorophenyl)methyl]-6-imino-7H-purin-8-yl]benzonitrile	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.2450	uM
6,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(4-phenylphenyl)methyl]chromen-4-one	414657: Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1 by competitive inhibition assay	ki	0.2700	uM
8-(4-chlorophenyl)-3-[(2,6-dichlorophenyl)methyl]-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.2880	uM
2-oxo-2-[[6-(pyrrolidine-1-carbonyl)-1,3-benzothiazol-2-yl]amino]ethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.3000	uM
2-[(6-methylsulfonyl-1,3-benzothiazol-2-yl)amino]-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.3000	uM
3-[(2,6-dichlorophenyl)methyl]-8-methyl-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.3060	uM
3-[2-(3-chlorophenyl)ethynyl]-6-hydroxy-2-[4-[2-oxo-2-(propylamino)ethoxy]phenyl]-1-benzofuran-5-carboxylic acid	755757: Inhibition of recombinant LMWPTP (unknown origin) using pNPP as substrate by spectrophotometric analysis	ic50	0.3400	uM
8-(3-chlorophenyl)-3-[(2,6-dichlorophenyl)methyl]-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	0.3800	uM
2-[(6-methyl-4-nitro-1,3-benzothiazol-2-yl)amino]-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.4000	uM
2-[(5-nitro-1,3-benzothiazol-2-yl)amino]-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.4000	uM
2-oxo-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]ethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	0.6000	uM
2-hydroxy-4-[4-[[2-(4-hydroxyphenyl)-4-oxochromen-3-yl]methyl]phenyl]benzoic acid	414644: Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1	ic50	0.7000	uM
3-[[2-methoxy-4-[(E)-[1-[(4-methylphenyl)methyl]-2,5-dioxoimidazolidin-4-ylidene]methyl]phenoxy]methyl]benzoic acid	2004707: Competitive inhibition of recombinant human ACP1 using pNPP as substrate assessed as inhibition constant preincubated with compound for 10 mins followed by substrate addition and measured by Lineweaver-Burk plot analysis	ki	0.9000	uM
4-[[(5Z)-2,4-dioxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid	300020: Inhibition of human low molecular weight Protein-tyrosine phosphatase IF1	ic50	0.9000	uM
2-[(6-nitro-1,3-benzothiazol-2-yl)amino]-2-oxo-1-phenylethanesulfonic acid	1713620: Competitive inhibition of His-tagged LMW-PTP isoform A (unknown origin) expressed in Escherichia coli BL21 cells using para-nitrophenyl phosphate as substrate by Lineweaver-Burk plot analysis	ki	1.0000	uM
3-[(2,4-dichlorophenyl)methyl]-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	1.0200	uM
2-[(5-bromo-6-morpholin-4-yl-3-pyridinyl)amino]-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	1.2000	uM
2-hydroxy-4-[4-[[7-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]methyl]phenyl]benzoic acid	414644: Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1	ic50	1.3000	uM
2-(3-bromo-4-morpholin-4-ylanilino)-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	1.5000	uM
azane;2-(1,8-naphthyridin-3-ylamino)-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	1.5000	uM
2-oxo-2-[(5-phenyl-1,3-thiazol-2-yl)amino]ethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	1.5000	uM
2-[(7-nitro-1,3-benzothiazol-2-yl)amino]-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	1.5000	uM
2-(1,3-benzothiazol-2-ylamino)-2-oxo-1-phenylethanesulfonic acid	1713621: Competitive inhibition of LMW-PTP isoform B (unknown origin) using para-nitrophenyl phosphate as substrate by Lineweaver-Burk plot analysis	ki	1.7000	uM
2-[(6-methyl-1,3-benzothiazol-2-yl)amino]-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	1.7000	uM
3-[(2-chlorophenyl)methyl]-7H-purin-6-imine	1778348: Inhibition of recombinant human LMPTP-A using OMFP or pNPP as substrate by fluorescence assay	ic50	1.9300	uM
2-(3,5-dibromo-4-methylanilino)-2-oxoethanesulfonic acid	1917631: Inhibition of His-tagged human LMW-PTP expressed in Escherichia coli BL21 using pNPP as substrate incubated for 10 mins by microplate reader based spectrophotometric analysis	ic50	2.2000	uM
3-[[4-(3,4-dihydroxyphenyl)phenyl]methyl]-7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one	414654: Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1 by mixed type inhibition assay	ki	2.2300	uM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	1182547: Inhibition of LMWPTP (unknown origin)	ic50	2.3400	uM
4-[[(5Z)-2,4-dioxo-5-[(4-phenylmethoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid	300020: Inhibition of human low molecular weight Protein-tyrosine phosphatase IF1	ic50	2.5000	uM
7-hydroxy-2-(4-hydroxyphenyl)-3-[(4-phenylphenyl)methyl]chromen-4-one	414654: Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1 by mixed type inhibition assay	ki	2.5000	uM

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, increases methylation, decreases expression	4
perfluorooctanoic acid	decreases expression, increases expression	2
chloropicrin	decreases expression	2
Nickel	increases expression	2
Tretinoin	decreases expression	2
Valproic Acid	affects expression, decreases methylation	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
alpha phellandrene	decreases expression	1
nitrophenylphosphate	increases hydrolysis, decreases reaction	1
sodium arsenate	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
decabromobiphenyl ether	increases expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	increases expression	1
ochratoxin A	increases expression	1
pentanal	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
perfluorohexanesulfonic acid	decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
quinocetone	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	increases expression	1

ChEMBL screening assays

84 unique, capped per target: 80 binding, 4 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1011832	Binding	Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1	Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. — Bioorg Med Chem
CHEMBL2114761	Functional	PubChem BioAssay. Dose response confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, in an orthogonal absorbance-based assay. (Class of assay: confirmatory)	PubChem BioAssay data set

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1AN	Abcam HEK293 ACP1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.